Biotech Values

[DewDiligence]

ABBV’s 4Q19 HCV sales should be $620-630M—below guidance—based on ENTA’s reported royalty revenue of $52.6M in the post I’m now replying to. If so, ABBV's 4Q19 HCV sales were down approximately 10% from the $698M figure in 3Q19 (#msg-152037090).

(ENTA’s royalty revenue can’t determine ABBV’s HCV sales exactly because there is a small contractual true-up [i.e. fudge factor] in the royalty calculation.)

ABBV reports 4Q19 results tomorrow (Friday) before the open.